Live Breaking News & Updates on Hannah Tsunemoto

Promising Minimum Inhibitory Concentration (MIC) activity in Phase I/II trial for urinary tract infections (UTI) and urosepsis with an increase in dosage expected to begin in the next several weeksExpansion of Phase I/II trial for diabetic foot infections (DFI) with efficacy achieved and now moving towards the initiation of a Phase III registrational trial in Indonesia scheduled to commence in Q3 2024RECCE® 327 (R327) shown to be effective against more than 300 strains of bacterial pathogens dur ....

United States , New South Wales , James Graham , Andrew Geddes , John Prendergast , Alanw Dunton , Michael Fitzhugh , Hannah Tsunemoto , Michele Dilizia , Us Department Of Defense , International Convention , American Society For Clinical Pharmacology , Drug Administration , Development Authority , Recce Pharmaceuticals Ltd , Biomedical Advanced Research , World Health Organization , Lifesci Communications , Health System Research Symposium , World Health Organization Recognition , Us Biomedical Advanced Research , Promising Minimum Inhibitory Concentration , Investigational New Drug , Western Australia , Pharmaceuticals Ltd , Annual General Meeting ,